Skip to Content

    Sales of multiple sclerosis drug Tecfidera helped treat this pharmaceutical firm to a hale 2014 (though recent results missed targets).

    41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

    Company Information

    Location
    Cambridge, MA
    Industry
    Pharmaceuticals
    Sector
    Health Care
    Fortune 500 Rank298
    Fortune 500 Profilehttp://fortune.com/fortune500/biogen-298/
    Current Streak1
    Years on List1
    CEO
    George A. Scangos
    Websitehttp://www.biogen.com

    Revenue, Net Income

    Revenue Past Four Quarters10,129
    Net Income Past Four Quarters3,277

    Growth Rates

    EPS 3 yr Annual Growth Rate35%
    Rev 3 yr Annual Growth Rate26%
    Total Return 3 yr Annual Rate41%
    Beat S&P 3 yr Total Return?
    yes

    Rank

    EPS Growth Rank69
    Revenue Growth Rank63
    Total Return Rank
    53